Only the part of the antibody (left) that binds to gluten is needed to create a product, which does not trigger an immune response.
In an industrial collaboration project, TU Wien has developed a medication that can alleviate or even completely eliminate the symptoms of celiac disease. It should be available as early as 2021. Celiac disease is a fairly common disease, affecting one to two percent of the European population. It is expressed as a hypersensitivity to gluten, a protein found in cereals such as wheat, barley or rye. Although efforts are already being made to treat celiac disease, the proposed drugs have an effect on the immune system. Possible side effects must therefore be examined very carefully. Although initial clinical studies are underway, they will not lead to a marketable product in the next few years.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
